Ocean Biomedical Files 8-K: Material Agreement & Equity Sales
Ticker: OCEA · Form: 8-K · Filed: Jul 23, 2024 · CIK: 1869974
Sentiment: neutral
Topics: material-definitive-agreement, equity-sale, financial-obligation
TL;DR
Ocean Biomedical inked a new deal creating financial obligations and sold unregistered equity.
AI Summary
Ocean Biomedical, Inc. entered into a material definitive agreement on July 22, 2024, related to the creation of a direct financial obligation. The company also reported unregistered sales of equity securities. This filing is a current report (8-K) filed on July 23, 2024.
Why It Matters
This 8-K filing indicates new financial obligations and equity transactions for Ocean Biomedical, which could impact its financial structure and shareholder value.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered sales of equity, which can introduce financial risks and dilution concerns.
Key Players & Entities
- Ocean Biomedical, Inc. (company) — Registrant
- July 22, 2024 (date) — Date of earliest event reported
- July 23, 2024 (date) — Filing date
FAQ
What type of material definitive agreement did Ocean Biomedical enter into?
The filing indicates the entry into a material definitive agreement that resulted in the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on July 22, 2024.
What other significant event is reported in this filing besides the material agreement?
The filing also reports unregistered sales of equity securities.
What is the SEC file number for Ocean Biomedical?
The SEC file number for Ocean Biomedical, Inc. is 001-40793.
What is the primary business of Ocean Biomedical, Inc. according to its SIC code?
Ocean Biomedical, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,163 words · 5 min read · ~4 pages · Grade level 12.5 · Accepted 2024-07-23 17:26:10
Key Financial Figures
- $0.0001 — ction 12(b) of the Act: Common Stock, $0.0001 par value OCEA The Nasdaq Stock Mar
- $11.50 — of common stock at an exercise price of $11.50 OCEAW The Nasdaq Stock Market LLC
- $7.675 — rrangements to fund up to an additional $7.675 in additional secured notes in conjunct
- $1.1 million — tutional investor. The first tranche of $1.1 million is being funded to various vendors on b
- $5.00 — the sales price of such shares is above $5.00 per share. The Company is also issuing
- $9,664,318 — rincipal amount of the Existing Note is $9,664,318.35, after giving effect to the Event of
- $2.7 million — institutional investors with regard to $2.7 million principal amount of promissory notes, p
- $1,662,084 — id interest through (i) the issuance of $1,662,084 worth of restricted common stock (at a
- $10 million — et proceeds to the Company of more than $10 million either in a public offering or private
Filing Documents
- form8-k.htm (8-K) — 51KB
- ex10-1.htm (EX-10.1) — 138KB
- 0001493152-24-028844.txt ( ) — 433KB
- ocea-20240722.xsd (EX-101.SCH) — 3KB
- ocea-20240722_def.xml (EX-101.DEF) — 26KB
- ocea-20240722_lab.xml (EX-101.LAB) — 36KB
- ocea-20240722_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 5KB
01 above
Item 1.01 above. Item 3.02 Unregistered Sales of Equity Securities See
01 above
Item 1.01 above. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 10.1 Exchange Agreement with Institutional Investor 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 23, 2024 OCEAN BIOMEDICAL, INC. By: /s/ Jolie Kahn Jolie Kahn Chief Financial Officer